Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598775 | 0.96 | SLC6A11 (0.48) | SLC6A11SLC6A1TP53MEN1CYP1A2 | |
| SCHEMBL15318305 | 0.95 | SLC6A11 (0.45) | SLC6A11SLC6A1PDE4BTP53LMNA | |
| SCHEMBL14866488 | 0.93 | SLC6A11 (0.47) | SLC6A11SLC6A1PDE4BTP53MEN1 | |
| SCHEMBL12582837 | 0.89 | SLC6A11 (0.41) | SLC6A11SLC6A1PDE4BTP53MEN1 | |
| SCHEMBL8660951 | 0.89 | SLC6A11 (0.45) | SLC6A11SLC6A1PDE4BTP53MEN1 | |
| SCHEMBL13575117 | 0.89 | SLC6A11 (0.45) | SLC6A11SLC6A1PDE4BTP53MEN1 | |
| SCHEMBL6834879 | 0.87 | PDE4B (0.54) | SLC6A11SLC6A1PDE4BTP53MEN1 | |
| SCHEMBL30613450 | 0.87 | SLC6A11 (0.42) | SLC6A11SLC6A1TP53MEN1CYP1A2 | |
| SCHEMBL28577719 | 0.86 | PDE4B (0.52) | SLC6A11SLC6A1PDE4BTP53MEN1 | |
| SCHEMBL12004675 | 0.85 | PDE4B (0.51) | SLC6A11SLC6A1PDE4BTP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097716-B2 | Interfering RNA duplex having blunt-ends and 3′-modifications | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| EP-2338995-A2 | Interfering RNA duplex having blunt-ends and 3'-modifications | Novartis AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-20090192113-A1 | Interfering RNA Duplex Having Blunt-Ends and 3`-Modifications | WEILER JAN | 2009-07-30 | — | — | US | disclosed |
| EP-1660657-A1 | INTERFERING RNA DUPLEX HAVING BLUNT-ENDS AND 3'-MODIFICATIONS | Novartis AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021749-A1 | INTERFERING RNA DUPLEX HAVING BLUNT-ENDS AND 3’-MODIFICATIONS | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192113-A1 | Interfering RNA Duplex Having Blunt-Ends and 3`-Modifications | NSUN3, NSUN2, RNGTT | SLC6A11 4805/4885SLC6A1 4837/4885PDE4B 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.